Navigation Links
Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
Date:12/13/2011

SAN DIEGO, Dec. 13, 2011 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo: 4503, Astellas) and Ambit Biosciences Corporation announced today that updated results from an interim analysis of a Phase 2 study of quizartinib (formerly AC220) in acute myeloid leukemia (AML) were presented at the 53rd Annual Meeting of the American Society of Hematology (ASH) in San Diego, California.  Data were also presented from two additional posters: one evaluating the pharmacodynamic effects of quizartinib in a pooled analysis from Phase 1 and Phase 2 studies, and another demonstrating that quizartinib enhances the activity of chemotherapy in an in vivo preclinical model of AML harboring the FLT3-ITD mutation.  The findings from those presentations are described below.

"AML is amongst the most challenging hematological malignancies to treat, and very few treatment advances have been made in several decades," said Jorge Cortes, M.D., Internist and Professor, Deputy Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, and primary investigator for the Phase 2 Study.  "A significant portion of AML patients have activating FLT3 mutations, and these patients have a particularly poor prognosis and often relapse or are refractory to current treatment options.  These clinical and preclinical results with quizartinib in FLT3-ITD positive AML are encouraging, and support conduct of further studies of this promising compound both as a monotherapy and in combination with other treatments."

A Phase 2 Open-Label, AC220 Monotherapy Efficacy Study in Patients with Refractory/Relapsed FLT3-ITD Positive Acute Myeloid Leukemia:  Updated Interim Results

The updated clinical response and safety data are from a planned interim analysis of a 62 patient subset from the ongoing Phase 2 multi-center study being conducted in the United States and Europe. Pat
'/>"/>

SOURCE Ambit Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
2. Ambit Biosciences Announces Transition in Company Leadership
3. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
4. Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
5. Astellas Awards Educational Scholarships to Six Transplant Recipients Who Embody the Spirit of Giving Back
6. Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
7. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
8. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
9. CV Therapeutics Board of Directors Rejects Astellas Unsolicited Proposal
10. CV Therapeutics Statement on Unsolicited Proposal From Astellas
11. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015 Working in collaboration ... in London , Richmond Pharmacology is the ... Phase 3 study for an investigational RNAi therapeutic being developed ... affecting the nerves and heart. Read press ... Based at St Georges University of ...
(Date:3/26/2015)... PRC Clinical, a Silicon-Valley based contract ... executive appointments effective immediately. , Mike Catelani will assume ... of the Board of Directors. Daniel Head is appointed ... will assume the position of Senior Director of Clinical ... (COO), has been appointed to the position of President ...
(Date:3/26/2015)... Neogen Corporation (NASDAQ: NEOG ) announced ... of fiscal 2015, which ended Feb. 28, increased 13% ... Earnings per share in the current quarter were $0.20, ... income increased 17% over prior year to $24,142,000, or ... share, for the same period a year ago. ...
(Date:3/26/2015)... Cranford, NJ (PRWEB) March 26, 2015 ... has partnered with researchers from Yale University’s School of ... provided by study participants during a 4 month-long project. ... impact of providing low income families with free access ... eating habits and diet-related health concerns like high blood ...
Breaking Biology Technology:PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3
... YORK, Aug. 24 ACCESS PHARMACEUTICALS, INC. ... company specializing in products for cancer and supportive care, ... Ric Zarzycki will give an invited presentation today on ... being held at the American Chemical Society,s ...
... READING, England and BEDMINSTER, N.J., Aug. 23 ... on oncology, pain, neurology and critical care sectors, announced ... Bedminster, New Jersey. Archimedes has offices in ... of therapeutics in Europe.  The opening of its US ...
... Scott & White Healthcare Board of Trustees Chairman ... & White Healthcare President and CEO Alfred B. Knight, ... President and CEO for the merged hospital and clinic ... assume the role of President of the Scott & ...
Cached Biology Technology:Access Pharmaceuticals Presents at American Chemical Society Annual Fall Meeting in Boston, MA 2Access Pharmaceuticals Presents at American Chemical Society Annual Fall Meeting in Boston, MA 3Access Pharmaceuticals Presents at American Chemical Society Annual Fall Meeting in Boston, MA 4Archimedes Pharma US Announces New US Headquarters In Bedminster, New Jersey 2Archimedes Pharma US Announces New US Headquarters In Bedminster, New Jersey 3Archimedes Pharma US Announces New US Headquarters In Bedminster, New Jersey 4Scott & White Healthcare President and CEO Alfred B. Knight, M.D. to Retire in 2011, Will Lead Foundation 2Scott & White Healthcare President and CEO Alfred B. Knight, M.D. to Retire in 2011, Will Lead Foundation 3Scott & White Healthcare President and CEO Alfred B. Knight, M.D. to Retire in 2011, Will Lead Foundation 4
(Date:3/11/2015)... 11, 2015   The Sync Project™ ... scientifically measure and harness music to improve health. ... and objective measurements of physiology, enabling the study ... in large populations. It is designed for medical ... perform rigorous studies and accelerate the discovery of ...
(Date:3/10/2015)... Utah , March 10, 2015   Tute ... interpretation, has been selected by next-generation sequencing company ... of whole exome and targeted gene panel interpretation. ... provider, has adopted the most current technologies to support ... genetic research. The company offers two types of exome ...
(Date:3/4/2015)... Mar. 04, 2015 Research and Markets ... of the "Global Biometrics Market Forecast and ... The market for biometric authentication systems is ... 14% till 2020 The driving forces ... security needs, government projects and constant development in ...
Breaking Biology News(10 mins):Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3
... new breed of permanently 'cheerful' mouse is providing hope ... a gene that can affect transmission of serotonin in ... role in mood, sleep and sexuality. By breeding mice ... a depression-resistant strain. The details of this research, which ...
... how a cell keeps its genetic material intact, scientists at ... vital to managing a yeast cell's energy. They discovered to ... led the cell to turn off 70 percent of its ... such a dramatic event," says Jef Boeke, Ph.D., Sc.D., a ...
... Howard Hughes Medical Institute researchers have discovered that neurons ... when the animals are adjusting to new experiences. The ... changing communication between neurons. , The researchers said their ... rewiring of the brain. This type of learning is ...
Cached Biology News:Ever-happy mice may hold key to new treatment of depression 2Johns hopkins researchers find link between cell's energy use and genome health 2Johns hopkins researchers find link between cell's energy use and genome health 3Long-term changes in experience cause neurons to sprout new long-lasting connections 2Long-term changes in experience cause neurons to sprout new long-lasting connections 3
Clarin Mounting Medium (Permanent environmentally safe mounting medium for general histology & cytology use)...
IHC Zinc Fixative - , 1000 ml Consult technical datasheet for details....
Rabbit polyclonal to JNK1 (phospho T183 + Y185) ( Abpromise for all tested applications). entrezGeneID: 5599 SwissProtID: P45983...
Cytofix Buffer 100 mls...
Biology Products: